180 Life Sciences EBITDA
Was ist das EBITDA von 180 Life Sciences?
EBITDA von 180 Life Sciences Corp. ist -$16.63
Was ist die Definition von EBITDA?
Das EBITDA ist das Ergebnis eines Unternehmens vor Zinsen, Steuern, Abschreibungen und Amortisationen und ist eine Buchhaltungsgröße, die anhand des Nettoergebnisses eines Unternehmens berechnet wird, bevor Zinsaufwendungen, Steuern, Abschreibungen und Amortisationen abgezogen werden, um die derzeitige operative Ertragskraft eines Unternehmens zu ermitteln.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 180 Life Sciences
Was macht 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Unternehmen mit ebitda ähnlich 180 Life Sciences
- Siyata Mobile hat EBITDA von -$16.69
- Galway Metals hat EBITDA von -CAD$16.69
- Galway Metals hat EBITDA von -CAD$16.69
- Amicus Therapeutics Inc hat EBITDA von -$16.68
- Bionomics hat EBITDA von -AUD$16.68
- Redx Pharma Plc hat EBITDA von -£16.65
- 180 Life Sciences hat EBITDA von -$16.63
- F-Secure Oyj hat EBITDA von -€16.57
- Aleafia Health Inc hat EBITDA von -CAD$16.57
- Clarus Corp hat EBITDA von -$16.56
- Ioneer hat EBITDA von -AUD$16.55
- Limeade hat EBITDA von -$16.52
- American Resources hat EBITDA von -$16.52